Please assess the completion status of the following clinical trial:

Trial Title: Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~* Normal electrocardiogram (ECG) at screening~* Hypertriglyceridemic patients must have a history of fasting serum triglycerides of at least 300 mg/dL (3.38 mmol/L) at screening or verifiable diagnosis of FCS~Exclusion Criteria:~* Clinically significant health concerns~* Regular use of alcohol within one month prior to Screening~* Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study~* Recent use of illicit drugs~* Use of more than two tobacco/nicotine containing or cannabis products per month within 6 months prior to drug administration (applicable only to Normal Healthy Volunteers)~Note: additional inclusion/exclusion criteria may apply, per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- ARO-APOC3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).